Ethos Discovery Stratified Outcomes for Lymphoma in Dogs (SOLID) Study: Informing Subclassification & Prognosis

June 20, 2025

Presentation Details

Primary Speaker:
Joelle M. Fenger, DVM, PhD, DACVIM (Oncology), Associate, Medical Oncologist, Ethos Discovery and Ethos Veterinary Health

Co-Presenter(s):
Heather M. Wilson-Robles, DVM, DACVIM (Oncology), Director of Research, Ethos Discovery
Ilona Holcomb, PhD, Director of Bioscience, ImpriMed, Inc.

Classification of LSA in dogs is based on anatomic location, histologic criteria, and immunophenotypic characteristics. Histologic classification currently follows the Revised European American Lymphoma/World Health Organization system incorporating anatomic, morphologic, and immunophenotypic criteria to enable accurate diagnosis and classification of LSA subtypes in dogs. However, LSA is not a single disease and classification by subtype becomes increasingly important as clinical studies are performed to correlate the various categories of disease with biological behavior, response to treatment, and prognosis. In people, genetic characterization of non-Hodgkin’s lymphoma is routinely used in diagnosis and subcategorization of LSA into prognostic categories. Investigations into the molecular landscape of canine LSA samples via cytogenetic and gene expression analysis have shown potential for both diagnostic and prognostic utility, but clinical correlates are currently preliminary and high evidence data defining genomic subclassifications of LSA and the identification of biomarkers associated with biologic behavior and response to treatment are currently lacking. We now seek to address these scientific and translational gaps through the launch of the Ethos Stratification of Outcomes for Lymphoma in Dogs (Ethos-SOLID) clinical trial which will identify molecular correlates for intermediate- to high-grade B and T cell canine multicentric LSA. Using complementary genomic, transcriptomic, and liquid biopsy platforms, we will identify and refine molecular subtypes of LSA characterized by molecular alterations. The goals of our study are to: (1) develop foundational knowledge and stratification of the distinct, molecular subtypes of canine LSA and (2) identify molecularly informed biomarkers associated with clinical response, disease burden, and cancer progression.

Learning Objectives:

  • Develop foundational knowledge and stratification of the distinct, molecular subtypes of canine lymphoma
  • Understand how Ethos Discovery is addressing the gaps related to our understanding of the molecular subclassification, disease monitoring, and molecularly-informed biomarkers of response for dogs with lymphoma through the prospective, nationwide, high quality evidentiary Ethos-SOLID clinical trial.
  • Summarize blood-based liquid biopsy diagnostics, ex vivo chemosensitivity and immunophenotyping assays and their clinical application in monitoring minimal residual disease and treatment response in canine lymphoma.

Presentations

Lumps, Lab Work, and a Little AI: A Tech’s Guide to Canine Lymphoma

Veterinary Cancer Society Annual Conference 2025
Learn More →

When AI Disappoints: Improving Outcomes with Real-World Clinical Data

Veterinary Cancer Society Annual Conference 2025
Learn More →

Optimizing the first line therapy of canine B-cell lymphomas via machine learning

Symposium on Artificial Intelligence in Veterinary Medicine (SAVY) 2.0
Learn More →

Boosting the power of AI-based treatment outcome predictions for canine lymphoma by combining tumor and germline genetic biomarkers and live-cell analytics

Veterinary Cancer Society Annual Conference 2024
Learn More →

Decoding Feline Lymphoma: From Diagnosis to Prognosis

Veterinary Cancer Society Annual Conference 2024
Learn More →

Novel Genetic Biomarkers of Chemotherapeutic Response in Canine Lymphoma and Improved Predictive Power With Integration of Machine Learning

Veterinary Cancer Society Annual Conference 2024
Learn More →

Improving Canine Lymphoma Treatment Outcomes by Individualizing Drug Selection using Machine-Learning-Based Predictive Models

Symposium on Artificial Intelligence in Veterinary Medicine (SAVY)
Learn More →

Treatment-specific risk stratification of feline lymphoma based on unsupervised clustering of flow cytometry results

World Veterinary Cancer Congress 2024
Learn More →

Dramatically increased clinical remission rates and survival times in dogs with high-grade T-cell lymphoma and relapsed B-cell lymphoma in clinical study of AI decision support

World Veterinary Cancer Congress 2024
Learn More →

AI-driven Personalized Medicine for Cancer Care

Precision Medicine World Conference 2024
Learn More →

Increased survival and remission rates in prospective study of relapsed B-cell lymphoma patients treated by oncologists using ImpriMed's AI predictions

Veterinary Cancer Society Annual Conference 2023
Learn More →

Identification of drug response biomarkers for canine lymphoma in large-scale NGS screen

Veterinary Cancer Society Annual Conference 2023
Learn More →

Impact of AI on clinical practice and outcome

Veterinary Cancer Society Annual Conference 2023
Learn More →

Canine Lymphoma Diagnostics Past, Present and Future: How AI technology and genetics are pushing the boundaries in veterinary medicine

Veterinary Cancer Society Annual Conference 2023
Learn More →

ImpriMed: AI-driven Personalized Medicine for Pet Cancer Care

Veterinary Cancer Society-Veterinary Society of Surgical Oncology Collaborative Conference 2023
Learn More →

Reinventing precision medicine: from dogs to humans

Precision Medicine World Conference 2023
Learn More →

ImpriMed Research Update

Veterinary Cancer Society Annual Conference 2022
Learn More →

Identification of Novel Predictive Biomarkers of Anticancer Drug Responses in Canine B-Cell Lymphoma Using Targeted NGS

Veterinary Cancer Society Annual Conference 2022
Learn More →

ImpriMed Research Update

Veterinary Cancer Society Mid-Year Conference 2022
Learn More →

Drugs predicted to be effective using artificial intelligence (AI) double the clinical response rate in canines with relapsed B-cell lymphoma

Veterinary Cancer Society Mid-Year Conference 2022
Learn More →

Precision medicine for pet cancer care

Animal Health, Nutrition and Technology Innovation Europe 2022
Learn More →

ImpriMed: Experiences from the eyes of an oncologist in clinical practice

Veterinary Cancer Society Annual Conference 2021
Learn More →

Predicting dynamic clinical outcomes of (L-)CHOP chemotherapy for canine lymphoma patients using an artificial intelligence model

Veterinary Cancer Society Annual Conference 2021
Learn More →

ImpriMed: A data-driven, personalized chemotherapy drug testing service for canine blood cancer patients

Veterinary Cancer Society Annual Conference 2021
Learn More →

Predicting likelihood of in vivo chemotherapy response in canine lymphoma using ex vivo drug sensitivity and immunophenotyping data in a machine learning model

Veterinary Cancer Society Annual Conference 2020
Learn More →

Individualizing chemotherapy for canine lymphoma based on ex vivo drug sensitivity test

World Veterinary Cancer Congress 2020
Learn More →

From dog to human: precision medicine for comparative oncology

Precision Medicine World Conference 2020
Learn More →

ImpriMed: precision medicine for pet cancer care

NYC Oncology Conference 2019
Learn More →

Individualizing chemotherapy for canine lymphoma based on ex vivo drug sensitivity test

Veterinary Cancer Society Annual Conference 2019
Learn More →